The impact of CD3 affinity-attenuation on T cell engaging bispecific antibodies: is it really that simple?

CD3 affinity reduction can effectively lower cytokine levels preclinically; however, it is crucial to consider all factors influencing the mode of action of TCEs. Prioritizing the use of the most translatable preclinical models is essential to identify the right candidates for further development.